[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Geener KJ, Feroze M, Geetha K, Jacob AJ: Papillary cystic tumor of pancreas--report of two cases. Indian J Pathol Microbiol; 2002 Jan;45(1):99-101
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary cystic tumor of pancreas--report of two cases.
  • Two cases of Papillary cystic tumor of pancreas--one metastasizing to lymph node and the other non-metastasizing are reported for their rare occurrence.
  • The histological findings seen in metastasizing tumor were capsular invasion, infiltration to surrounding pancreatic tissue and vascular invasion with metastasis to lymph node.
  • Adjuvant chemotherapy was given for metastasizing tumor and patient is symptom free after 56 month.
  • [MeSH-major] Carcinoma, Papillary / pathology. Pancreas / pathology. Pancreatic Cyst / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12593574.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Sperti C, Berselli M, Pasquali C, Pastorelli D, Pedrazzoli S: Aggressive behaviour of solid-pseudopapillary tumor of the pancreas in adults: a case report and review of the literature. World J Gastroenterol; 2008 Feb 14;14(6):960-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive behaviour of solid-pseudopapillary tumor of the pancreas in adults: a case report and review of the literature.
  • Solid-pseudopapillary tumor (SPT) is a rare neoplasm of the pancreas that usually occurs in young females.
  • It is generally considered a low-grade malignant tumor that can remain asymptomatic for several years.
  • Between 1986 and 2006, 282 cystic tumors of the pancreas were observed.
  • This was diagnosed in a 49-year-old female 13 years after the sonographic evidence of a small pancreatic cystic lesion interpreted as a pseudocyst.
  • The tumor invaded a long segment of the portal-mesenteric vein confluence, and was removed with a total pancreatectomy, resection of the portal vein and reconstruction with the internal jugular vein.
  • Chemotherapy with different drugs was started.
  • Twenty-five patients with invasion of the portal vein and/or of mesenteric vessels were retrieved from the literature, 16 recent patients with tumor relapse after potentially curative resection were also retrieved.
  • The best treatment remains a radical resection whenever possible, even in locally advanced or metastatic disease.
  • The role of chemotherapy, and/or radiotherapy, is still to be defined.
  • [MeSH-major] Cystadenoma, Papillary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Middle Aged. Recurrence. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):887-9 [10919054.001]
  • [Cites] J Surg Oncol. 2007 Jun 15;95(8):640-4 [17477365.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):35-40 [11833495.001]
  • [Cites] Pancreatology. 2002;2(5):495-8 [12378119.001]
  • [Cites] ANZ J Surg. 2003 Jun;73(6):410-5 [12801340.001]
  • [Cites] Ann Chir. 2003 Oct;128(8):543-8 [14559306.001]
  • [Cites] J Surg Oncol. 2004 Mar 15;85(4):193-8 [14991875.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):291-3 [15043751.001]
  • [Cites] J Surg Oncol. 1983 Feb;22(2):115-7 [6823124.001]
  • [Cites] Ann Surg. 1983 Mar;197(3):272-5 [6830334.001]
  • [Cites] Cancer. 1985 Dec 15;56(12):2783-5 [4052952.001]
  • [Cites] Gastroenterol Jpn. 1987 Jun;22(3):379-84 [2442059.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):283-91 [2295051.001]
  • [Cites] Surgery. 1990 Sep;108(3):475-80 [2396191.001]
  • [Cites] Acta Pathol Jpn. 1991 Oct;41(10):763-70 [1812691.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):82-92 [8416730.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):433-6 [8457156.001]
  • [Cites] Med Pediatr Oncol. 1993;21(5):365-7 [8492753.001]
  • [Cites] Surgery. 1995 Nov;118(5):821-8 [7482268.001]
  • [Cites] Gastroenterol Clin Biol. 1997;21(10):789-93 [9587521.001]
  • [Cites] Pathol Int. 1999 Mar;49(3):231-4 [10338079.001]
  • [Cites] Cancer. 1961 Nov-Dec;14:1272-94 [13909709.001]
  • [Cites] Lancet Oncol. 2005 Mar;6(3):185-6 [15737835.001]
  • [Cites] World J Gastroenterol. 2005 Mar 7;11(9):1403-9 [15761986.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):512-9 [15767807.001]
  • [Cites] Pancreatology. 2005;5(2-3):289-94 [15855828.001]
  • [Cites] J Am Coll Surg. 2005 Jun;200(6):965-72 [15922212.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 Aug;4(3):456-9 [16109536.001]
  • [Cites] Pathol Int. 2005 Dec;55(12):792-6 [16287495.001]
  • [Cites] J Surg Res. 2006 Apr;131(2):276-82 [16457845.001]
  • [Cites] Pancreas. 2006 Apr;32(3):276-80 [16628083.001]
  • [Cites] Br J Surg. 2006 Jun;93(6):733-7 [16609955.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1157-63 [16778826.001]
  • [Cites] Pancreatology. 2006;6(4):291-6 [16636602.001]
  • [Cites] JOP. 2006;7(6):635-42 [17095844.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(6):587-90 [17139438.001]
  • [Cites] Am J Clin Oncol. 2006 Dec;29(6):639-40 [17149006.001]
  • [Cites] Rev Esp Enferm Dig. 2006 Nov;98(11):809-16 [17198473.001]
  • [Cites] JOP. 2007;8(2):223-7 [17356247.001]
  • [Cites] J Surg Oncol. 2001 Apr;76(4):289-96 [11320522.001]
  • (PMID = 18240360.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2687069
  •  go-up   go-down


3. Freda F, Procaccini E, Ruggiero R, Antropoli M, Manganiello A, Nunziata L, Petronella P, Lo Schiavo F: Solid-cystic pseudopapillary tumor of pancreas: description of two cases and literature review. Tumori; 2007 Sep-Oct;93(5):522-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-cystic pseudopapillary tumor of pancreas: description of two cases and literature review.
  • The authors report the cases of two young female patients aged 17 and 27 years who underwent surgery for a rare tumor of the pancreas, Frantz's tumor or solid-cystic pseudopapillary tumor.
  • Solid-cystic pseudopapillary tumor of the pancreas is a rare tumor, accounting for 2.7% of pancreatic exocrine tumors.
  • Due to their rareness and behavior, they are often associated with diagnostic and therapeutic problems.
  • In most cases surgical treatment is curative and neither chemotherapy nor radiotherapy should be added.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatic Pseudocyst / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038892.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography showed an 18 x 16 cm right pelvic tumor, with both cystic and solid components, ascites and bilateral massive pleural effusion.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • Adjuvant chemotherapy with carboplatin and paclitaxel was prescribed postoperatively, but the malignancy was not controlled due to lung, brain and vulva metastases.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Carcinoembryonic Antigen / metabolism. Combined Modality Therapy. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Necrosis. Vulvar Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175478.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


5. Omae T, Takahashi M, Sasajima T, Sugawara T, Kinouchi H, Higashiyama N, Mizoi K: [Supratentorial primitive neuroectodermal tumor: report of a surgical case]. No Shinkei Geka; 2004 Jun;32(6):619-25
Genetic Alliance. consumer health - Supratentorial primitive neuroectodermal tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Supratentorial primitive neuroectodermal tumor: report of a surgical case].
  • A 15-year-old girl presented with a one-month history of headache and vomiting.
  • CT scans showed a huge, solid and cystic tumor with calcification, occupying the left anterior cranial fossa.
  • The solid portion of the tumor was hypointense on T1-weighted images, slightly hyperintense on T2-weighted images, hyperintense on diffusion- weighted images, isointense on fluid-attenuated inversion recovery (FLAIR) images, and strongly enhanced after administration of contrast medium.
  • The expansile tumor had a broad attachment to the dura matter of the anterior cranial fossa.
  • The patient underwent an uneventful extirpation of the tumor.
  • Microscopically, the solid tumor contained small, round poorly-differentiated cells with pleomorphic nuclei and brisk mitotic activity.
  • The tumor cells were immunoreactive for synaptophysin and GFAP, whereas lack of MIC2 gene product expression was confirmed using the monoclonal antibody 12E7.
  • The patient successively received a dose of 30.4Gy to the whole spine and Linac stereotactic radiotherapy with a marginal dose of 16.8Gy at the tumor bed.
  • Three months after radiotherapy the patient received chemotherapy using carboplatin and etoposide.
  • Follow-up MR images showed no evidence of recurrent tumor 5 months after the radiochemotherapy.
  • On the basis of MR findings on both diffusion-weighted and FLAIR images, preoperative diagnosis of sPNET may be important for choosing appropriate therapeutic strategies for this tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15352632.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Uchida K, Joseph JM, Gapany C, Chardot C: Modified digestive reconstruction with midgut transposition after pylorus-preserving pancreaticoduodenectomy for pancreatic head tumor in childhood. J Pediatr Surg; 2008 Oct;43(10):1932-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified digestive reconstruction with midgut transposition after pylorus-preserving pancreaticoduodenectomy for pancreatic head tumor in childhood.
  • We describe a new procedure of digestive reconstruction after pylorus-preserving pancreaticoduodenectomy in a 13-year-old girl presenting with a large solid and papillary epithelial neoplasm of the pancreatic head.
  • A midgut transposition (like in a cure of midgut malrotation) was easily performed after tumor removal with minimal additional dissection.
  • [MeSH-major] Cystadenoma, Papillary / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Adolescent. Anastomosis, Roux-en-Y. Enzymes / therapeutic use. Exocrine Pancreatic Insufficiency / drug therapy. Exocrine Pancreatic Insufficiency / etiology. Female. Humans. Jejunum / surgery. Pylorus. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926236.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzymes
  •  go-up   go-down


7. Kanter J, Wilson DB, Strasberg S: Downsizing to resectability of a large solid and cystic papillary tumor of the pancreas by single-agent chemotherapy. J Pediatr Surg; 2009 Oct;44(10):e23-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downsizing to resectability of a large solid and cystic papillary tumor of the pancreas by single-agent chemotherapy.
  • Solid and cystic pseudopapillary tumor (SCPT) is an uncommon cancer that typically affects young women.
  • There are anecdotal reports of the use of neoadjuvant chemotherapy or radiation therapy for patients with unresectable tumors.
  • We report the case of a 14-year-old female with SCPT who was successfully downsized with gemcitabine before definitive surgical resection.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Cystadenoma, Papillary / pathology. Cystadenoma, Papillary / surgery. Deoxycytidine / analogs & derivatives. Neoadjuvant Therapy / methods. Pancreas / drug effects. Pancreas / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Biopsy / methods. Female. Humans. Pancreatectomy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19853735.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


8. Brandt WD, Matsui W, Rosenberg JE, He X, Ling S, Schaeffer EM, Berman DM: Urothelial carcinoma: stem cells on the edge. Cancer Metastasis Rev; 2009 Dec;28(3-4):291-304
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This variability likely stems from epigenetic and genetic influences, either stochastic or hardwired by cell type-specific lineage programs.
  • That differentiation underlies tumor cell heterogeneity was elegantly demonstrated in hematopoietic tumors, in which rare primitive cells (cancer stem cells (CSCs)) resembling normal hematopoietic stem cells are ultimately responsible for tumor growth and viability.
  • Because of the compelling clinical implications CSCs pose--across the entire spectrum of cancers--investigators applied the CSC model to cancers arising in tissues with crudely understood differentiation programs.
  • The recent identification of urothelial differentiation programs in urothelial carcinomas (UroCas) supports the idea that solid epithelial cancers (carcinomas) develop and differentiate analogously to normal epithelia and provides new insights about the spatial localization and molecular makeup of carcinoma CSCs.
  • Importantly, CSCs from invasive UroCas (UroCSCs) appear well situated to exchange important signals with adjacent stroma, to escape immune surveillance, and to survive cytotoxic therapy.
  • These signals have potential roles in treatment resistance and many participate in druggable cellular pathways.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 May;18(5):523-7 [18392048.001]
  • [Cites] Br J Urol. 1994 May;73(5):516-21 [8012773.001]
  • [Cites] Nature. 2006 May 25;441(7092):518-22 [16633340.001]
  • [Cites] Nature. 2006 May 25;441(7092):418-9 [16724049.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):818-22 [16862118.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1167-74 [16998484.001]
  • [Cites] Acta Haematol. 2007;117(1):8-15 [17095854.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] J Clin Invest. 2007 Feb;117(2):314-25 [17256055.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Endocrinology. 2007 Apr;148(4):1797-803 [17234707.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1175-83 [17476347.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Cell. 2007 Jun 15;129(6):1097-110 [17574023.001]
  • [Cites] Science. 2007 Jul 20;317(5836):337 [17641192.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Cell Cycle. 2007 Oct 1;6(19):2332-8 [17786053.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Science. 2007 Dec 14;318(5857):1722; author reply 1722 [18079385.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):190-7 [18172311.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] Cell. 2008 Feb 22;132(4):598-611 [18295578.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] Am J Physiol Renal Physiol. 2008 Jun;294(6):F1415-21 [18367656.001]
  • [Cites] PLoS One. 2008;3(6):e2428 [18560594.001]
  • [Cites] Cancer Invest. 2008 Aug;26(7):725-33 [18608209.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):755-68 [18784658.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3543-53 [18948588.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Int J Cancer. 2009 Jan 1;124(1):103-8 [18844223.001]
  • [Cites] Curr Opin Oncol. 2009 Jan;21(1):41-6 [19125017.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Mol Cancer Ther. 2009 Feb;8(2):458-68 [19174556.001]
  • [Cites] Genes Dev. 2009 Mar 15;23(6):675-80 [19261747.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):780-3 [19194462.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3364-73 [19351829.001]
  • [Cites] J Int Med Res. 2009 May-Jun;37(3):621-30 [19589244.001]
  • [Cites] Cell. 2009 Jul 23;138(2):226-8 [19632173.001]
  • [Cites] Cell. 2009 Jul 23;138(2):286-99 [19632179.001]
  • [Cites] Stem Cells. 2009 Jul;27(7):1487-95 [19544456.001]
  • [Cites] Cell. 2009 Aug 21;138(4):645-59 [19682730.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14016-21 [19666525.001]
  • [Cites] Ann N Y Acad Sci. 2009 Aug;1171:59-76 [19723038.001]
  • [Cites] Int J Cancer. 2009 Nov 1;125(9):2095-103 [19637316.001]
  • [Cites] Ann N Y Acad Sci. 2009 Sep;1176:144-9 [19796242.001]
  • [Cites] Stem Cells Dev. 2009 Dec;18(10):1515-22 [19260804.001]
  • [Cites] Oncol Rep. 2000 Jan-Feb;7(1):13-6 [10601583.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1758-66 [10688835.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Jun;278(6):F867-74 [10836974.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):851-6 [10997813.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1955-9 [11395371.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1028-34 [11533706.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Blood. 2002 Jan 1;99(1):319-25 [11756187.001]
  • [Cites] Int J Oncol. 2002 May;20(5):905-11 [11956582.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] J Urol. 2002 Aug;168(2):709-17 [12131357.001]
  • [Cites] J Pathol. 2002 Oct;198(2):245-51 [12237885.001]
  • [Cites] Int J Cancer. 2003 Jan 20;103(3):328-34 [12471615.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):90-6 [12469123.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Jan 21;55(1):3-29 [12535572.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):493-504 [12875970.001]
  • [Cites] N Engl J Med. 2003 Aug 28;349(9):859-66 [12944571.001]
  • [Cites] J Pathol. 2003 Oct;201(2):204-12 [14517837.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):465-78 [14968126.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5467-77 [15100288.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4040-8 [15173019.001]
  • [Cites] Genes Dev. 2004 Aug 1;18(15):1875-85 [15289459.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7183-90 [15492230.001]
  • [Cites] Am J Obstet Gynecol. 1969 Mar 15;103(6):810-22 [5765964.001]
  • [Cites] J Anat. 1972 Sep;112(Pt 3):433-55 [4636798.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 1):2326-9 [1277137.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Virchows Arch B Cell Pathol. 1976 Oct 1;21(4):279-98 [824809.001]
  • [Cites] Science. 1983 Jun 10;220(4602):1175-7 [6304875.001]
  • [Cites] Blood. 1990 May 15;75(10):1947-50 [2337669.001]
  • [Cites] J Biol Chem. 1990 Nov 5;265(31):19170-9 [2229070.001]
  • [Cites] Cancer Treat Res. 1991;53:335-64 [1672086.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2898-902 [8499629.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Acta Anat (Basel). 1996;155(3):163-71 [8870784.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1217-21 [9102201.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Br J Cancer. 1998;77(2):319-24 [9461004.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1090-4 [9515785.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):829-34 [9563875.001]
  • [Cites] Am J Obstet Gynecol. 1998 Apr;178(4):641-9 [9579425.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3512-7 [10416618.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):17-23 [15652746.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3790-8 [15897578.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4415-29 [15958626.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6 [15939524.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6207-19 [16024622.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4602-8 [16034041.001]
  • [Cites] Dev Cell. 2005 Aug;9(2):173-83 [16054025.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):713-25 [16110317.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7709-19 [16278391.001]
  • [Cites] Eur J Cancer. 2006 Jan;42(1):50-4 [16330205.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):383-91 [16428476.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1554-9 [16261162.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2109-16 [16609023.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(2):CD006018 [16625650.001]
  • [Cites] Nature. 2006 May 25;441(7092):475-82 [16598206.001]
  • (PMID = 20012172.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA067751-13; United States / NIDDK NIH HHS / DK / R01DK072000; United States / NCI NIH HHS / CA / T32 CA067751-13; United States / NIDDK NIH HHS / DK / R01 DK072000-04; United States / NCI NIH HHS / CA / P01CA077664; United States / NIDDK NIH HHS / DK / R01 DK072000; United States / NCI NIH HHS / CA / CA077664-10; United States / NCI NIH HHS / CA / P01 CA077664-10; United States / NIDDK NIH HHS / DK / DK072000-04; United States / NCI NIH HHS / CA / P01 CA077664
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Wnt Proteins
  • [Number-of-references] 121
  • [Other-IDs] NLM/ NIHMS224847; NLM/ PMC2930269
  •  go-up   go-down


9. Alexandrescu DT, O'Boyle K, Feliz A, Fueg A, Wiernik PH: Metastatic solid-pseudopapillary tumour of the pancreas: clinico-biological correlates and management. Clin Oncol (R Coll Radiol); 2005 Aug;17(5):358-63
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic solid-pseudopapillary tumour of the pancreas: clinico-biological correlates and management.
  • Solid-pseudopapillary tumour of the pancreas is a rare neoplasm of young women, currently categorised in the World Health Organization classification under exocrine pancreatic tumours.
  • We describe two patients with solid-pseudopapillary tumour of the pancreas.
  • A smaller, localised tumour in an unusually young white man was surgically excised with no evidence of recurrence after 2 years.
  • A literature review was carried out, and the main clinico-pathological features and strategies of treatment of solid-pseudopapillary tumour of the pancreas are presented.
  • Pathological, genetic and molecular features distinguish solid-pseudopapillary tumours from pancreatic ductal adenocarcinoma.
  • Furthermore, neuroendocrine differentiation can be found focally in occasional cases of solid-pseudopapillary tumour.
  • Chemotherapy and radiation therapy are used in rare cases when resection is not possible.
  • No current chemotherapy regimens are considered standard in the treatment of this tumour.
  • A rational chemotherapy protocol for such a rare tumour needs to consider its origin and clinical behaviour.
  • However, the indolent clinical progression of solid-pseudopapillary tumours is similar to that of pancreatic neuroendocrine tumour.
  • [MeSH-major] Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16097567.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Hah JO, Park WK, Lee NH, Choi JH: Preoperative chemotherapy and intraoperative radiofrequency ablation for unresectable solid pseudopapillary tumor of the pancreas. J Pediatr Hematol Oncol; 2007 Dec;29(12):851-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemotherapy and intraoperative radiofrequency ablation for unresectable solid pseudopapillary tumor of the pancreas.
  • Solid pseudopapillary tumor (SPT) is rare primary tumor of the pancreas with low malignant potential affecting adolescent or young women.
  • Radical surgical resection is the definitive treatment for long-term survival even in the patients with metastases.
  • She received preoperative chemotherapy with cisplatinum, ifosfamide, etoposide, and vincristine followed by intraoperative radiofrequency ablation of metastatic liver lesions with surgical resection of the primary tumor successfully.
  • [MeSH-major] Carcinoma, Papillary / surgery. Carcinoma, Papillary / therapy. Catheter Ablation. Pancreatic Neoplasms / surgery. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090937.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Soloni P, Cecchetto G, Dall'igna P, Carli M, Toffolutti T, Bisogno G: Management of unresectable solid papillary cystic tumor of the pancreas. A case report and literature review. J Pediatr Surg; 2010 May;45(5):e1-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of unresectable solid papillary cystic tumor of the pancreas. A case report and literature review.
  • Pancreatic solid papillary cystic tumor is a rare neoplasm with an excellent prognosis if surgical excision is complete.
  • We report on a case and review 47 more cases extracted from the published literature to assess the treatment options when solid papillary cystic tumor is considered unresectable.
  • Chemotherapy and radiotherapy were beneficial in a limited number of patients, but therapeutic decisions must be made bearing in mind that patients may be long-term survivors without any treatment because of the tumor's slow growth.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Papillary / drug therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Cystic, Mucinous, and Serous / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Child. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20438906.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Snajdauf J, Rygl M, Petru O, Kalousova J, Kuklova P, Mixa V, Keil R, Hribal Z: Duodenum-sparing technique of head resection in solid pseudopapillary tumor of the pancreas in children. Eur J Pediatr Surg; 2009 Dec;19(6):354-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenum-sparing technique of head resection in solid pseudopapillary tumor of the pancreas in children.
  • AIM OF STUDY: Aim of the study was to assess the complications and long-term results in children operated on for solid pseudopapillary tumor of the pancreas (SPTP) between 1993-2008 at the authors' institution with a focus on a novel duodenum-sparing technique to treat tumors of the head of the pancreas.
  • METHODS: Retrospective analysis was performed of patient data including demographics, diagnostic measures, the operative technique focusing on tumor of the head of the pancreas, complications and long-term results.
  • In 7 patients the tumor was localized in the head of the pancreas, in 4 patients in the tail, and in 2 patients both the body and tail were involved.
  • Patients with body and tail involvement underwent distal pancreatic resection.
  • She developed a biliary fistula which closed after three weeks with endoscopic stenting.
  • One patient with head resection developed a biliary fistula which closed after two weeks of stenting.
  • All patients are alive without tumor recurrence at 6 months to 16 years after operation.
  • CONCLUSION: SPTP is a rare pancreatic tumor with a low degree of malignancy.
  • No perioperative chemotherapy is necessary.
  • [MeSH-major] Biliary Fistula / etiology. Carcinoma, Papillary / surgery. Duodenum. Pancreatectomy / adverse effects. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 19821226.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Kanoh A, Seko A, Ideo H, Yoshida M, Nomoto M, Yonezawa S, Sakamoto M, Kannagi R, Yamashita K: Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas. Glycoconj J; 2006 Jul;23(5-6):453-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas.
  • Mucinous and clear cell adenocarcinomas are the major histological types of ovarian epithelial cancer and are associated with a poor prognosis due to their resistance to chemotherapy.
  • A novel tumor marker specific for ovarian mucinous and clear cell adenocarcinomas would be helpful for overcoming these serious diseases.
  • We showed previously by enzymological characterization and RT-PCR that colonic mucinous adenocarcinoma tissues ectopically express GlcNAc6ST-2, a member of the carbohydrate 6-O-sulfotransferase family (Seko, A. et al. (2002) Glycobiology 12, 379-388).
  • Here, we prepared a GlcNAc6ST-2-specific polyclonal antibody for immunohistochemical analysis and found that GlcNAc6ST-2 is ectopically expressed by not only colonic mucinous adenocarcinomas but also ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • In contrast, solid serous adenocarcinomas, endometrioid adenocarcinomas, and mucinous adenomas expressed GlcNAc6ST-2 much less frequently or not at all.
  • These results indicate that GlcNAc6ST-2 would be a novel tumor antigen that is specifically expressed in ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / enzymology. Drug Resistance, Neoplasm / physiology. Ovarian Neoplasms / enzymology. Sulfotransferases / genetics
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / biosynthesis. Antigens, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Middle Aged. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biol Markers. 1998 Oct-Dec;13(4):179-87 [10228898.001]
  • [Cites] J Cell Biol. 1999 May 17;145(4):899-910 [10330415.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):193-8 [10188718.001]
  • [Cites] Science. 1990 Nov 23;250(4984):1130-2 [1701274.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 24;263(2):543-9 [10491328.001]
  • [Cites] Am J Clin Pathol. 1991 Dec;96(6):711-6 [1720922.001]
  • [Cites] BMJ. 1996 Nov 30;313(7069):1355-8 [8956699.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):47747-50 [11585845.001]
  • [Cites] J Biol Chem. 1998 May 1;273(18):11225-33 [9556613.001]
  • [Cites] Gynecol Oncol. 1993 Jan;48(1):38-49 [8423020.001]
  • [Cites] Cell. 2001 Jun 29;105(7):957-69 [11439191.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2127-35 [10232599.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] Obstet Gynecol. 1993 Jul;82(1):143-7 [8515915.001]
  • [Cites] Cancer Res. 1993 Jan 15;53(2):354-61 [7678075.001]
  • [Cites] Oncol Res. 1999;11(5):233-41 [10608618.001]
  • [Cites] J Biol Chem. 1998 Aug 28;273(35):22577-83 [9712885.001]
  • [Cites] Immunity. 2001 Aug;15(2):237-47 [11520459.001]
  • [Cites] J Biol Chem. 2002 Feb 8;277(6):3979-84 [11726653.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1544-50 [9537262.001]
  • [Cites] Glycobiology. 2002 Jun;12(6):379-88 [12107080.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):285-91 [12619114.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1138-50 [1904477.001]
  • [Cites] Glycobiology. 2000 Sep;10(9):919-29 [10988253.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):33-5 [8261457.001]
  • [Cites] Int J Oncol. 1999 Jun;14(6):1057-61 [10339657.001]
  • (PMID = 16897186.001).
  • [ISSN] 0282-0080
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.- / carbohydrate sulfotransferases
  •  go-up   go-down


14. Rebhandl W, Felberbauer FX, Puig S, Paya K, Hochschorner S, Barlan M, Horcher E: Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children: report of four cases and review of the literature. J Surg Oncol; 2001 Apr;76(4):289-96
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children: report of four cases and review of the literature.
  • BACKGROUND: Solid-pseudopapillary tumor of the pancreas (SPT) is an exceptionally rare neoplasm in children.
  • PATIENTS AND METHODS: A cumulative review of the tumor's clinicopathological characteristics from the world's literature is presented.
  • Surgical procedures included three distal pancreatectomies and one partial duodenopancreatectomy (Whipple procedure).
  • Chemotherapy was initiated for this patient.
  • It is mandatory to establish this diagnosis since complete surgical removal of the tumor even in case of metastases or local invasion offers an excellent prognosis.
  • [MeSH-major] Cystadenoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11320522.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


15. Moshel YA, Elliott RE, Monoky DJ, Wisoff JH: Role of diffusion tensor imaging in resection of thalamic juvenile pilocytic astrocytoma. J Neurosurg Pediatr; 2009 Dec;4(6):495-505
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diffusion tensor (DT) imaging and white matter tractography can identify the location of the PLIC in relation to the tumor and may be useful in planning the operative trajectory.
  • This result was compared with the location of the PLIC determined by a blinded radiologist with the use of DT imaging.
  • The utility of DT imaging in determining the surgical approach to a thalamic JPA, degree of resection, and neurological outcomes were all evaluated.
  • Gross-total resection of all cystic and solid tumor components was confirmed on postoperative imaging in all cases.


16. Foltys D, Moench C, Burck I, Hoppe-Lotichius M, Schad A, Teufel A, Heise M, Otto G: [The solid pseudopapillary tumor (SPT)--a rare neoplasm of the pancreas]. Z Gastroenterol; 2008 Jul;46(7):689-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The solid pseudopapillary tumor (SPT)--a rare neoplasm of the pancreas].
  • [Transliterated title] Der solid pseudopapilläre Pankreastumor (SPT)--eine seltene Raumforderung der Bauchspeicheldrüse.
  • BACKGROUND: In general, the rare SPT is a tumour of low malignancy predominantly affecting young women.
  • In exceptional cases the tumour presents as solid pseudopapillary carcinoma (SPC) with typical malignant features and even metastases.
  • Unresectable liver metastases can be treated with RFA, TACE or chemotherapy.
  • For radical tumour removal a pancreato-duodenectomy (n = 3), a distal pancreatectomy (n = 1) and an enucleation (n = 1) were performed.
  • We encountered a mean tumour diameter of 8 cm (range: 6-15 cm), an angioinvasion (3/5) and a lymphatic infiltration (1/5).
  • Chemotherapy has resulted in a survival of over 98 months in a case of SPC with liver metastases.
  • CONCLUSION: SPT is a tumour of low malignancy.
  • Chemotherapy may prolong survival in SPC with unresectable metastases.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / surgery. Pancreatectomy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618380.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Yang F, Jin C, Long J, Yu XJ, Xu J, Di Y, Li J, Fu de L, Ni QX: Solid pseudopapillary tumor of the pancreas: a case series of 26 consecutive patients. Am J Surg; 2009 Aug;198(2):210-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pseudopapillary tumor of the pancreas: a case series of 26 consecutive patients.
  • OBJECTIVE: Solid pseudopapillary tumor (SPT) of the pancreas, which predominantly affects young women, is a relatively indolent entity with favorable prognosis.
  • Clinicopathologic factors were compared between benign and malignant cases to determine what features of the tumor could suggest malignant potential.
  • The neoplasm was localized in the pancreatic head/neck in 14 patients and in the body/tail in 12 patients.
  • All of the tumors-including 8 pancreaticoduodenectomies, 10 distal pancreatectomies, 6 local resections, 1 total pancreatectomy, and 1 central pancreatectomy-were resected successfully.
  • No patient received chemotherapy or radiotherapy after surgery.
  • One of the 2 patients with malignant SPT, in whom Ki-67 immunoreactivity was >25%, developed local recurrence with liver metastasis 4 months and died 6 months after surgery.
  • CONCLUSIONS: SPT is a rare neoplasm with low malignant potential.
  • Characteristic computed axial tomography and magnetic resonance imaging scans combined with age and sex profile should be sufficient for the decision to operate.
  • [MeSH-major] Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19268906.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Choi SH, Kim SM, Oh JT, Park JY, Seo JM, Lee SK: Solid pseudopapillary tumor of the pancreas: a multicenter study of 23 pediatric cases. J Pediatr Surg; 2006 Dec;41(12):1992-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pseudopapillary tumor of the pancreas: a multicenter study of 23 pediatric cases.
  • BACKGROUND/PURPOSE: Solid pseudopapillary tumor (SPT) is a very rare form of childhood pancreatic tumor.
  • This study was intended to analyze the clinicopathologic characteristics of this tumor in childhood.
  • Five (22%) were male, with a male-to-female ratio of 1:3.6.
  • Operative procedures performed were pylorus-preserving pancreaticoduodenectomy (n = 6, 26.1%), distal pancreatectomy (n = 7, 30.4%), distal pancreatectomy with splenectomy (n = 7, 30.4%).
  • One patient showed multiple liver metastasis 3 months after the initial operation and required adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17161189.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


19. Fritzsche FR, Kristiansen G, Frauenfelder T, Opitz I, Bode P, Moch H, Montani M: Large mixed germ cell tumor in a young patient presenting as an intrapulmonary mass. Pathol Res Pract; 2009;205(8):572-8
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large mixed germ cell tumor in a young patient presenting as an intrapulmonary mass.
  • We present the case of a 26-year-old man with a bland medical history, who presented to the general practitioner because of severe cough and dyspnea.
  • The chest X-ray revealed a massive organ-displacing tumor in the right chest not delineable from the mediastinum.
  • The subsequent needle core biopsy was diagnostic for a mixed germ cell tumor comprising immature teratoma and seminoma.
  • After an initially good response to chemotherapy, tumor markers and tumor size were progressive.
  • The right-sided pneumonectomy revealed an intrapulmonary tumor with cystic and solid components, hemorrhage, and necrosis with a tumor diameter of 18cm.
  • Histology confirmed a teratoma with mature and immature components accompanied by residual seminomatous tumor cells.
  • We describe this exceptional large intrapulmonary germ cell tumor and discuss the spectrum of such rare tumors.
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Disease Progression. Fatal Outcome. Humans. Male. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201104.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Coulson LE, Kong CS, Zaloudek C: Epithelioid trophoblastic tumor of the uterus in a postmenopausal woman: a case report and review of the literature. Am J Surg Pathol; 2000 Nov;24(11):1558-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid trophoblastic tumor of the uterus in a postmenopausal woman: a case report and review of the literature.
  • We report an epithelioid trophoblastic tumor (ETT), a recently delineated type of gestational trophoblastic tumor (GTT), discovered in the uterus of a 66-year-old woman.
  • She had been treated for a hydatidiform mole 17 years previously without chemotherapy.
  • The resected uterus contained a solid/cystic tumor located entirely within the myometrium.
  • Microscopically, there was an epithelial-like growth pattern.
  • The tumor was circumscribed, with a pushing border, and the tumor cells grew in cords, nests, and sheets within which were aggregates of hyaline material and necrotic debris.
  • Most tumor cells were mononuclear and had an epithelioid appearance with distinct cell borders, eosinophilic cytoplasm, and nuclei with occasional indistinct nucleoli.
  • The histologic and immunohistochemical features were characteristic of ETT, and helped to distinguish the tumor from other trophoblastic tumors and squamous cell carcinoma.
  • Our findings indicate that ETT, like other types of GTT, can occur in postmenopausal women, even years after a gestational event.
  • [MeSH-major] Epithelioid Cells / pathology. Postmenopause. Trophoblastic Tumor, Placental Site / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Neoplasm Proteins / analysis. Pregnancy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11075860.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Number-of-references] 13
  •  go-up   go-down


21. Cavallini A, Falconi M, Bortesi L, Crippa S, Barugola G, Butturini G: Pancreatoblastoma in adults: a review of the literature. Pancreatology; 2009;9(1-2):73-80
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pancreatoblastoma is a very uncommon neoplasm in adults and its management represents a great challenge with regards to different treatment options.
  • After a search on the Medline database, a review of all cases was performed as well, focusing on clinical, radiological and hystopathological features and treatment options.
  • In general, despite aggressive treatment, pancreatoblastoma in adults is associated with poorer outcome than in children, with a median survival time of 18.5 months.
  • CONCLUSION: Pancreatoblastoma is a rare neoplasm in adults.
  • The differential diagnosis includes nonfunctional pancreatic endocrine tumor, acinar cell carcinoma, solid pseudopapillary tumor and adenocarcinoma.
  • Surgical resection is the only treatment associated with long-term survival.
  • Chemotherapy may play a role as palliative treatment in advanced disease.

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel and IAP.
  • (PMID = 19077457.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 36
  •  go-up   go-down


22. Salvia R, Festa L, Butturini G, Tonsi A, Sartori N, Biasutti C, Capelli P, Pederzoli P: Pancreatic cystic tumors. Minerva Chir; 2004 Apr;59(2):185-207
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cystic tumors.
  • Cystic tumors of the pancreas are less frequent than other tumors in neoplastic pancreatic pathology, but in recent years the literature has reported an increasing number.
  • After the first report by Becourt in 1830, cystic tumors were classified into 2 different types by Compagno and Oertel in 1978: benign tumors with glycogen-rich cells and mucinous cystic neoplasms with overt and latent malignancy.
  • The WHO classification of exocrine tumors of the pancreas, published in 1996, is based on the histopathological features of the epithelial wall, which are the main factor in differential diagnosis with cystic lesions of the pancreas.
  • Thanks to the knowledge acquired up to now, a surgical procedure is not always required because the therapeutic choice is conditioned by the correct classification of this heterogeneous group of tumors.
  • Clinical signs are not really useful in the clinical work up, most patients have no symptoms and when clinical signs are present, they may help us to pinpoint the organ of origin but never to identify the type of pathology.
  • In the last few years, the great improvement in imaging has enabled us not only to discriminate cystic from solid lesions, but also to identify the features of the lesions and label them preoperatively.
  • More invasive diagnostic procedures such as fine needle aspiration and intracystic fluid tumor marker level are not really useful because they are not sensitive and the cystic wall can show different degrees of dysplasia and de-epithelialization.
  • Therefore, we must analyze all the information we have, such as age, sex, clinical history, location of the tumor and radiological features, in order to avoid the mistake of treating a cystic neoplasm as a benign lesion or as a pseudocyst, as described in the literature.
  • Except for inoperable cases due to the critical condition of the patient or non-resectable lesions, surgical treatment differs with the diagnosis.
  • Cystic tumors of the pancreas, therefore, are a heterogeneous group of tumors, with a real problem regarding differential diagnosis between neoplastic and inflammatory lesions.
  • Even with a proper work up, some perplexity may remain about the nature of the lesion and in these cases the surgical procedure has a therapeutic value as well as playing a diagnostic role.
  • The role of surgery is central in the treatment of these tumors because it could be curative when complete resection is possible.
  • In this way, the lack of good therapeutic results with chemotherapy and radiotherapy force the surgeon to go ahead with the procedure.
  • Intraductal papillary mucinous neoplasms represent a new and, from the epidemiological point of view, important chapter in the world of cystic tumors.
  • In the last few years the therapeutic approach has changed thanks to new knowledge of the biological behavior of these tumors.
  • In fact, from a surgical approach in all cases, we are now discussing the possibility of a follow-up not only for asymptomatic serous cystadenomas but also for the little branch side intraductal papillary mucinous neoplasms (IPMNs) in critical patients.
  • A follow-up could be planned even for solid pseudopapillary tumors but it seems risky to leave untreated big tumors in young patients without a certain diagnosis and with so few studies reported in the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15238892.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng; ita
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 45
  •  go-up   go-down


23. Shorter NA, Glick RD, Klimstra DS, Brennan MF, Laquaglia MP: Malignant pancreatic tumors in childhood and adolescence: The Memorial Sloan-Kettering experience, 1967 to present. J Pediatr Surg; 2002 Jun;37(6):887-92
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant tumors of the pancreas are uncommon in children and adolescents and only recently have the most common tumor types been well characterized.
  • As a result, the treatment approach to these patients has yet to be standardized, and much of the information available in the literature, particularly with regard to the role of chemotherapy and radiation, is anecdotal.
  • The pathologic types were pancreatoblastoma, 5; solid pseudopapillary tumor, 7; acinar cell carcinoma, 1; nonfunctioning pancreatic endocrine neoplasm, 1; malignant VIPoma, 1; and PNET, 2.
  • A complete resection of the primary tumor was achieved in 82%, and 12 of 15 are alive, 10 with no evidence of disease.
  • Chemotherapy or radiation were used in selected cases.
  • The roles of chemotherapy and radiation remain undefined.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / therapy. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Neoplasm Recurrence, Local. Pancreatectomy. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Treatment Outcome. Vipoma / pathology. Vipoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12037756.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Kotchetkov R, Cinatl J, Krivtchik AA, Vogel JU, Matousek J, Pouckova P, Kornhuber B, Schwabe D, Cinatl J Jr: Selective activity of BS-RNase against anaplastic thyroid cancer. Anticancer Res; 2001 Mar-Apr;21(2A):1035-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Anaplastic thyroid carcinoma is an aggressive solid tumor that fails to adequately respond to any known chemotherapeutic regimen.
  • The development of effective chemotherapy agents would provide the best chance for long-term survival of patients.
  • MATERIALS AND METHODS: The cytotoxic effects of bovine seminal ribonuclease (BS-RNase) against thyroid carcinoma cell lines with different degrees of differentiation in comparison to non-malignant cells, including human foreskin fibroblasts (HFF) and retinal pigment epithelial cells (RPE), were tested using the MTT dye reduction assay.
  • RESULTS: All the tumor cell lines exhibited marked sensitivity against BS-RNase in comparison to HFF and RPE cells.
  • The greatest growth inhibition was seen in the 8505C line, while IC50 values for papillary (B-CPAP) and poorly-differentiated thyroid carcinoma cells were about 6-fold higher.
  • In vivo treatment induced significant tumor regression after the course of 20 consecutive days.
  • No apparent toxic effects of BS-RNase toward non-malignant cells were observed during the in vivo treatment.
  • After cessation of therapy (day 20) tumor volume continued to decrease and the tumor was no longer detectable after 30 days of treatment induction in all animals.
  • CONCLUSION: BS-RNase may have beneficial effects for treatment of aggressive anaplastic thyroid cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endoribonucleases / therapeutic use. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antigens, CD95 / biosynthesis. Apoptosis. Cattle. Fas Ligand Protein. Female. Humans. Membrane Glycoproteins / biosynthesis. Mice. Mice, Nude. Neoplasm Transplantation. Neoplasms, Experimental. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11396137.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Fasl protein, mouse; 0 / Membrane Glycoproteins; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.1.- / Endoribonucleases; EC 3.1.27.- / ribonuclease SPL
  •  go-up   go-down


25. Gurevich LE, Kazantseva IA: [A solid-pseudopapillary tumors of the pancreas]. Arkh Patol; 2010 Mar-Apr;72(2):52-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A solid-pseudopapillary tumors of the pancreas].
  • The review presents an update of solid-pseudopapillary pancreatic tumors, a rare and inadequately studied type of tumors that are predominantly encountered in girls and young women.
  • It discusses the problems in the diagnosis based on the histological and imunophenotypical uniqueness of these tumors, which allows them to be differentiated from other types of pancreatic tumors with a less favorable prognosis.
  • The correct diagnosis of a solid-pseudopapillary tumor determines the management tactic that requires no radiation or chemotherapy in the vast majority.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698319.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 50
  •  go-up   go-down


26. Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, Gayther SA: Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol; 2007 Feb;211(3):286-95
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours.
  • Genetic analysis of solid tumours using DNA or cDNA expression microarrays may enable individualized treatment based on the profiles of genetic changes that are identified from each patient.
  • This could result in better response to adjuvant chemotherapy and, consequently, improved clinical outcome.
  • So far, most research studies that have tested the efficacy of such an approach have sampled only single areas of neoplastic tissue from tumours; this assumes that the genetic profile within solid tumours is homogeneous throughout.
  • The aim of this study was to evaluate the extent of genetic intra-tumour heterogeneity (ITH) within a series of epithelial ovarian cancers.
  • Several different regions (five to eight regions) of tumour tissue from 16 grade 3, serous epithelial ovarian cancers were analysed for genetic alterations using a combination of microsatellite analysis and single nucleotide polymorphism (SNP) analysis, in order to establish the extent of ITH.
  • Maximum parsimony tree analysis was applied to the genetic data from each tumour to evaluate the clonal relationship between different regions within tumours.
  • Evolutionary analysis of microsatellite data suggested that the origin of all tumours was monoclonal, but that subsequent clonal divergence created mixed populations of genetically distinct cells within the tumour.
  • The frequent occurrence of ITH within epithelial ovarian cancers may have implications for the interpretation of genetic data generated from emerging technologies such as DNA and mRNA expression microarrays, and their use in the clinical management of patients with ovarian cancer.
  • The basis of genetic ITH and the possible implications for molecular approaches to clinical diagnosis of ovarian cancers may apply to other tumour types.
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Gene Expression Regulation, Neoplastic. Genetic Heterogeneity. Ovarian Neoplasms / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Alleles. Disease Progression. Female. Genotype. Humans. Microsatellite Instability. Microsatellite Repeats. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 17154249.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


27. Maffuz A, Bustamante Fde T, Silva JA, Torres-Vargas S: Preoperative gemcitabine for unresectable, solid pseudopapillary tumour of the pancreas. Lancet Oncol; 2005 Mar;6(3):185-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative gemcitabine for unresectable, solid pseudopapillary tumour of the pancreas.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / surgery. Female. Humans. Neoadjuvant Therapy. Pancreaticoduodenectomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737835.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down






Advertisement